Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST study of first-line ovarian cancer treatment with niraparib plus dostarlimab
NL-OMON59490Phase 3Completed
- Sponsor
- TESARO, Inc.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dostarlimab and niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by TESARO, Inc. Primary endpoint: Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
dostarlimabniraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON59490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59490.